ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

VNDA Vanda Pharmaceuticals Inc

4.97
0.29 (6.20%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Vanda Pharmaceuticals Inc NASDAQ:VNDA NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.29 6.20% 4.97 3.75 6.49 4.91 4.7001 4.71 681,346 05:00:08

IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Vanda Pharmaceuticals...

04/03/2019 3:59pm

Business Wire


Vanda Pharmaceuticals (NASDAQ:VNDA)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Vanda Pharmaceuticals Charts.

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Vanda Pharmaceuticals Inc. (“Vanda” or “the Company”) (NASDAQ: VNDA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's shares between November 4, 2015 and February 11, 2019, inclusive (the “Class Period”), are encouraged to contact the firm before April 26, 2019.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall, or Sherin Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Vanda engaged in a fraudulent off-label usage scheme with its drugs Fanapt and Hetlioz. The Company abused Medicare, Medicaid, and Tricare programs to receive drug reimbursements from the government. Due to this fraudulent activity, the Company faced legal action by the government. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Vanda, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

The Schall Law FirmBrian Schall, Esq.Sherin Mahdavian, Esq.www.schallfirm.comOffice: 310-301-3335Cell: 424-303-1964info@schallfirm.com

1 Year Vanda Pharmaceuticals Chart

1 Year Vanda Pharmaceuticals Chart

1 Month Vanda Pharmaceuticals Chart

1 Month Vanda Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock